Rivastigmine

Alzheimer's disease: the amyloid cascade hypothesis

Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works

SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE

DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · see citing works

Protein aggregation and neurodegenerative disease

Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · see citing works

Alzheimer’s disease

Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works

Alzheimer's disease

Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616 · see citing works

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw

Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943 · see citing works

Targeting acetylcholinesterase and butyrylcholinesterase in dementia

Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654 · see citing works

Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa

Gänger, S., & Schindowski, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030116 · Cited by 447 · see citing works

Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting

Fazil, M., Md, S., Haque, S., Kumar, M., Baboota, S., Sahni, J. K., & Ali, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.013 · Cited by 379 · see citing works

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332 · see citing works

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer's disease

Polinsky, R. J. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80127-6 · Cited by 323 · see citing works

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial

Reading, P., Luce, A., & McKeith, I. G. (2001) · Movement Disorders · doi:10.1002/mds.1204 · Cited by 269 · see citing works

Potential medicinal plants for CNS disorders: an overview

Kumar, V. (2006) · Phytotherapy Research · doi:10.1002/ptr.1970 · Cited by 268 · see citing works

Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition

Ballard, C. G. (2002) · European Neurology · doi:10.1159/000047952 · Cited by 261 · see citing works

Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia

Mesulam, M. M., & Geula, C. (1994) · Annals of Neurology · doi:10.1002/ana.410360506 · Cited by 259 · see citing works

Rivastigmine for Alzheimer's disease

Birks, J., & Evans, J. G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub3 · Cited by 247 · see citing works

Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters

Shah, B. M., Khunt, D., Bhatt, H., Misra, M., & Padh, H. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.07.002 · Cited by 237 · see citing works

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

Kandiah, N., Pai, M.-C., Senanarong, V., Looi, I., Ampil, E. R., Park, K. W., Karanam, A. K., & Christopher, S. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s129145 · Cited by 232 · see citing works

Subicular efferents are organized mostly as parallel projections: A double-labeling, retrograde-tracing study in the rat

Naber, P. A., & Witter, M. P. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980413)393:3 · Cited by 219 · see citing works

Rivastigmine

Spencer, C. M., & Noble, S. (1998) · Drugs & Aging · doi:10.2165/00002512-199813050-00005 · Cited by 187 · see citing works

Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer’s Disease

Thomas, J., Thomas, C. J., Radcliffe, J., & Itsiopoulos, C. (2015) · BioMed Research International · doi:10.1155/2015/172801 · Cited by 173 · see citing works

Rivastigmine in the treatment of Alzheimer's disease: an update

Onor, M. L., Trevisiol, M., & Aguglia, E. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.17 · Cited by 162 · see citing works

Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimers Disease

Castro, A., & Martı́nez, A. (2001) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557013406864 · Cited by 160 · see citing works

An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine

Khoury, R., Rajamanickam, J., & Grossberg, G. T. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617750555 · Cited by 156 · see citing works

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months

Darreh‐Shori, T., Almkvist, O., Guan, Z. Z., Garlind, A., Strandberg, B., Svensson, A., Soreq, H., Hellström‐Lindahl, E., & Nordberg, A. K. (2002) · Neurology · doi:10.1212/wnl.59.4.563 · Cited by 154 · see citing works

Design, Synthesis, and Biological Evaluation of Conformationally Restricted Rivastigmine Analogues

Bolognesi, M. L., Bartolini, M., Cavalli, A., Andrisano, V., Rosini, M., Minarini, A., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049782n · Cited by 150 · see citing works

Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization

Shah, B. M., Misra, M., Shishoo, C. J., & Padh, H. (2014) · Drug Delivery · doi:10.3109/10717544.2013.878857 · Cited by 136 · see citing works

Treatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations

Farlow, M. R., Miller, M. L., & Pejović, V. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000122962 · Cited by 130 · see citing works

Genetic markers for diagnosis and pathogenesis of Alzheimer's disease

Kim, D., Yeo, S. H., Park, J.-M., Choi, J. Y., Lee, T.-H., Park, S. Y., Ock, M. S., Eo, J., Kim, H., & Cha, H. (2014) · Gene · doi:10.1016/j.gene.2014.05.031 · Cited by 128 · see citing works

Cholinergic activity and amyloid precursor protein metabolism

Roberson, M. R. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00016-7 · Cited by 127 · see citing works

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease

Cutler, N. R., Polinsky, R. J., Srarnek, J. J., Enz, A., Jhee, S. S., Mancione, L., Hourani, J., & Zolnouni, P. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb00645.x · Cited by 123 · see citing works

A review of rivastigmine: A reversible cholinesterase inhibitor

Williams, B. R., Nazarians, A., & Gill, M. A. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80160-1 · Cited by 122 · see citing works

Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property

Singh, B., Sharma, B., Jaggi, A. S., & Singh, N. (2012) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320312459977 · Cited by 117 · see citing works

Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety

Nagpal, K., Singh, S. K., & Mishra, D. N. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.04.024 · Cited by 116 · see citing works

Plaque-associated lipids in Alzheimer’s diseased brain tissue visualized by nonlinear microscopy

Kiškis, J., Fink, H., Nyberg, L. K., Thyr, J., Li, J., & Enejder, A. M. K. (2015) · Scientific Reports · doi:10.1038/srep13489 · Cited by 113 · see citing works

Acetylcholinesterase‐rich neurons of the human cerebral cortex: Cytoarchitectonic and ontogenetic patterns of distribution

Mesulam, M., & Geula, C. (1991) · The Journal of Comparative Neurology · doi:10.1002/cne.903060202 · Cited by 105 · see citing works

Brain targeted rivastigmine mucoadhesive thermosensitive In situ gel: Optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution

Abouhussein, D. M. N., Khattab, A., Bayoumi, N. A., Mahmoud, A. F., & Sakr, T. M. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.021 · Cited by 105 · see citing works

Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease

Winblad, B. G., Kawata, A. K., Beusterien, K. M., Thomas, S. K., Wimo, A. B., Lane, R. M., Fillit, H. M., & Blesa, R. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1806 · Cited by 101 · see citing works

Long‐lasting acetylcholinesterase splice variations in anticholinesterase‐treated Alzheimer's disease patients

Darreh‐Shori, T., Hellström‐Lindahl, E., Flores‐Flores, C., Guan, Z. Z., Soreq, H., & Nordberg, A. K. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02230.x · Cited by 92 · see citing works

Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer’s disease

Bastiat, G., Plourde, F., Motulsky, A., Fürtös, A., Dumont, Y., Quirion, R., Fuhrmann, G., & Leroux, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.009 · Cited by 87 · see citing works

Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate

Simon, A., Amaro, M. I., Cabral, L. M., Healy, A. M., & de Sousa, V. P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.01.066 · Cited by 84 · see citing works

Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.

Poirier, J. (2002) · PubMed · Cited by 74 · see citing works

Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease

Chen, Z., Digiacomo, M., Tu, Y., Gu, Q., Wang, S., Yang, X., Chu, J., Chen, Q., Han, Y., Chen, J., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.052 · Cited by 74 · see citing works

Preferential Cerebrospinal Fluid Acetylcholinesterase Inhibition by Rivastigmine in Humans

Kennedy, J. S., Polinsky, R. J., Johnson, B. W., Loosen, P. T., Enz, A., Laplanche, R., Schmidt, D. E., Mancione, L., Parris, W. C. V., & Ebert, M. H. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912000-00005 · Cited by 73 · see citing works

Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies

Salatin, S., Barar, J., Barzegar-Jalali, M., Adibkia, K., & Jelvehgari, M. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.08.031 · Cited by 72 · see citing works

Three years survival in patients with a clinical diagnosis of dementia with Lewy bodies

Walker, Z., Allen, R. L., Shergill, S. S., Mullan, E., & Katona, C. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(200003)15:3 · Cited by 71 · see citing works

Optimization of rivastigmine nanoemulsion for enhanced brain delivery: In-vivo and toxicity evaluation

Haider, M. F., Khan, S., Gaba, B., Alam, T., Baboota, S., Ali, J., & Ali, A. (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.01.123 · Cited by 68 · see citing works

Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer??s disease

Venneri, A., McGeown, W. J., & Shanks, M. F. (2005) · Neuroreport · doi:10.1097/00001756-200502080-00006 · Cited by 65 · see citing works

Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors

Wang, L., Wang, Y., Tian, Y., Shang, J., Sun, X., Chen, H., Wang, H., & Tan, W. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.002 · Cited by 63 · see citing works

Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients

Almkvist, O., Darreh‐Shori, T., Stefanova, E. D., Spiegel, R., & Nordberg, A. K. (2004) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00757.x · Cited by 55 · see citing works

Alzheimer´s Disease associated with Psychiatric Comorbidities

Garcez, M. L., Falchetti, A. C. B., Mina, F., & Budni, J. (2015) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201520140716 · Cited by 55 · see citing works

Neuroprotective effects of Rosa damascena extract on learning and memory in a rat model of amyloid-β-induced Alzheimer`s disease

Karimipour, M., Esfandiary, E., Mardani, M., Ghanadian, M., Alaei, H., Mohammadnejad, D., & Esmaeili, A. (2015) · Advanced Biomedical Research · doi:10.4103/2277-9175.161512 · Cited by 52 · see citing works

Improved chemoenzymatic asymmetric synthesis of (S)-Rivastigmine

Fuchs, M., Koszelewski, D., Tauber, K., Sattler, J. H., Banko, W., Holzer, A. K., Pickl, M., Kroutil, W., & Faber, K. (2012) · Tetrahedron · doi:10.1016/j.tet.2012.06.031 · Cited by 52 · see citing works

An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting

Aguglia, E., Onor, M. L., Saina, M., & Maso, E. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x6273 · Cited by 52 · see citing works

Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: An approach for enhancing cholinergic neurotransmission

Amenta, F., Tayebati, S. K., Vitali, D., & Tullio, M. A. D. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.017 · Cited by 48 · see citing works

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

Adler, G., Mueller, B., & Articus, K. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12374 · Cited by 47 · see citing works

Controlled delivery of rivastigmine using transdermal patch for effective management of alzheimer's disease

Malaiya, M. K., Jain, A., Hurkat, P., Jain, A., & Jain, D. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.03.030 · Cited by 43 · see citing works

Differential Efficacy of Treatment with Acetylcholinesterase Inhibitors in Patients with Mild and Moderate Alzheimer’s Disease over a 6-Month Period

Pousa, S. L., Estrada, A. T., Garre‐Olmo, J., Nierga, I. P., Gallego, M. L., Vilalta-Franch, M., Hernández-Ferràndiz, M., Muñoz, V. M., Isern-Vila, A., Gelada-Batlle, E., et al. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000083498 · Cited by 40 · see citing works

Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model

Anand, A., Arya, M., Kaithwas, G., Singh, G., & Saraf, S. A. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.11.021 · Cited by 35 · see citing works

Designing Second Generation Anti-Alzheimer Compounds as Inhibitors of Human Acetylcholinesterase: Computational Screening of Synthetic Molecules and Dietary Phytochemicals

Amat-ur-Rasool, H., & Ahmed, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136509 · Cited by 30 · see citing works

Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease

Nesi, G., Chen, Q., Sestito, S., Digiacomo, M., Yang, X., Wang, S., Pi, R., & Rapposelli, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.006 · Cited by 27 · see citing works

Asymmetric synthesis of an enantiomerically pure rivastigmine intermediate using ketoreductase

Sethi, M. K., Bhandya, S. R., Maddur, N., Shukla, R., Kumar, A., & Mittapalli, V. S. N. J. (2013) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2013.01.023 · Cited by 21 · see citing works

In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus

Trabace, L., Coluccia, A. M. L., Gaetani, S., Tattoli, M., Cagiano, R., Pietra, C., Kendrick, K. M., & Cuomo, V. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02266-6 · Cited by 21 · see citing works

Rivastigmine as a Modulator of the Neuronal Glutamate Transporter rEAAC1 mRNA Expression

Andin, J., Enz, A., Gentsch, C., & Marcusson, J. O. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000080966 · Cited by 20 · see citing works

Treatment of cognitive impairment in Alzheimer's disease

Burns, A. S. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/aburns · Cited by 20 · see citing works

Stereoselective synthesis of a key chiral intermediate of (S)-Rivastigmine by AKR-GDH recombinant whole cells

Xie, P., Zhou, X., & Zheng, L. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.11.016 · Cited by 16 · see citing works

Evaluación de la conveniencia del cambio de vía de administración de rivastigmina en pacientes con enfermedad de Alzheimer

Blesa, R., Boada, M., Parra, C. M., Saladié, D. G. I., Almagro, C. A., & Vázquez, A. L. G. (2011) · Neurología · doi:10.1016/j.nrl.2010.10.007 · Cited by 10 · see citing works

Topography of cortical thinning areas associated with hippocampal atrophy (HA) in patients with Alzheimer's disease (AD)

Kim, G. H., Jeon, S., Seo, S. W., Kim, M.-J., Kim, J. H., Roh, J. H., Shin, J. S., Kim, C. H., Im, K., Lee, M.-J., et al. (2011) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2011.10.013 · Cited by 10 · see citing works

Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan

Chang, C., Chou, T., Chang, C., Chen, T., Hu, C., Fuh, J., Wang, W., Chen, C., Hsu, W., & Huang, C. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.013 · Cited by 10 · see citing works

Modulation of human motor cortex excitability by the cholinesterase inhibitor rivastigmine

Langguth, B., Bauer, E., Feix, S., Landgrebe, M., Binder, H., Sand, P. G., Hajak, G., & Eichhammer, P. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.01.008 · Cited by 9 · see citing works

A specific two-pulse release of rivastigmine using a modified time-controlled delivery system: A proof of concept case study

Penhasi, A., & Gomberg, M. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.08.009 · Cited by 7 · see citing works

The dementias

Mulley, G. P., & Jones, R. W. (2003) · Clinical Medicine · doi:10.7861/clinmedicine.3-5-404 · Cited by 4 · see citing works

Multi-target-directed therapeutic strategies for Alzheimer's disease: controlling amyloid-β aggregation, metal ion homeostasis, and enzyme inhibition

Yoo, J., Lee, J., Ahn, B., Han, J., & Lim, M. H. (2025) · Chemical Science · doi:10.1039/d4sc06762b · Cited by 74 · see citing works

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works

HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine

Santos, R. X., Melis, V., Goatman, E. A., Leith, M., Baddeley, T. C., Storey, J. M. D., Riedel, G., Wischik, C. M., & Harrington, C. R. (2022) · Biomedicines · doi:10.3390/biomedicines10040867 · Cited by 8 · see citing works

Ex vivo and in vivo Assessment of Paliperidone Thermal in situ Gel as Nasal-to-Brain Delivery System in Rats

Ismail, M. F., & Al-Gawhari, F. J. (2025) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v9i2.2460 · Cited by 1 · see citing works

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status

Gottwald, M. D., & Rozanski, R. I. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1673 · Cited by 91 · see citing works

Rivastigmine may improve functioning in mild to moderate Alzheimer's disease

(1999) · BMJ · doi:10.1136/bmj.318.7184.0c

Rivastigmina: una revisión de su eficacia clínica

Spiegel, R. (2002) · Revista de Neurología · doi:10.33588/rn.3509.2002002 · Cited by 6 · see citing works

P.5.c.001 An experimental study of the effects of rivastigmine and memantine alone and in combination on learning and memory in rats

Yanev, P. G., Dimitrova, D. S., & Getova, D. P. (2013) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(13)70865-4

Rivastigmine in the treatment of Alzheimer's disease: an update

Onor, M. L., Trevisiol, M., & Aguglia, E. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.17 · Cited by 162 · see citing works